Introduction
Cellular microparticles are plasma membrane vesicles of <1.5 µm in diameter, mainly composed of lipids and proteins, which are released into the circulation by bloodcells and vascular cells during cellular activation or apoptosis. 1 Microparticles are heterogeneous, differing in size, as well as in phospholipid -and protein composition. In addition, microparticles display some specific cell surface proteins that indicate their cellular origin. Depending on the cellular process and the cellular origin triggering their formation, the outer surfaces of cellular microparticles may contain phosphatidylserine, which provides a suitable anionic phospholipid surface for assembly of the tenase and prothrombinase complexes, and they may express tissue factor (TF), the primary initiator of coagulation. 2 Such phosphatidylserine-and/or TF-bearing microparticles may contribute to the pathogenesis of thrombosis in different diseases, including cancer-associated thrombosis and sepsis. 3 Indeed, the numbers and characteristics of circulating microparticles have been found to be altered in many vascular diseases associated with an increased risk of both arterial and venous thrombosis. In particular, elevated numbers of platelet-derived microparticles have been described in diabetes mellitus, 4 acute coronary syndrome, 5 myocardial infarction 6 and disseminated intravascular coagulation. 7 Elevated levels of endothelialderived microparticles have been found in venous thromboembolism 8 and in the antiphosholipid syndrome. 9 The majority (more than 90%) of microparticles in healthy controls are of platelet origin, whereas less than 10% originate from granulocytes and less than 5% from endothelial cells, red blood cells and monocytes. 10 Essential thrombocythemia (ET) is a chronic myeloproliferative disease characterized by an increased risk of both arterial and venous thrombosis. At the time of diagnosis approximately 20% of ET patients have had a major thrombotic event and approximately another 20% will subsequently have an event. 11 This makes venous and (more often) arterial thrombosis the leading causes of morbidity and mortality in ET. Established risk factors for thrombosis in ET are older age (over 60 years) and previous thrombotic events. 12 Recently, leukocytosis has been identified as an additional risk factor. 11, 13, 14 Numerous mechanisms, including blood hyperviscosity and quantitative/qualitative abnormalities of blood cells, have been advocated to be at the origin of the hypercoagulable state in these patients. 15 An increased number of platelets, 16 abnormal function of platelets, 12 activation of platelets and leukocytes, 17, 18 their interaction to form plateletleukocyte aggregates, 17 and endothelial activation may all contribute to the increased thrombotic state in ET, which is still not completely understood. In the present study, we investigated the numbers and the procoagulant potential of circulating microparticles in a group of patients with ET, using flow cytometry and a thrombin generation assay, respectively. In addition, levels of mature von Willebrand factor (vWF) and propeptide, and soluble E-selectin were determined in the same plasma samples as a measure of ongoing endothelial activation.
Design and Methods

Study subjects
Twenty-one consecutive ET patients (8 males and 13 females, median age: 58, range: 34-83 years) were enrolled at the Hematology Department of Bergamo Hospital (Italy), after giving informed consent. Patients were diagnosed as having ET according to the Polycythemia Vera Study Group (PVSG) criteria. 19 All investigations were approved by the local ethical committee (Comitato di Bioetica, Ospedali Riuniti, Bergamo, Italy). The patients' characteristics are shown in Table 1 . Nine patients were heterozygous carriers for the JAK2 V617F mutation. At the time of the sample collection 18 patients were receiving treatment with aspirin, 8 with hydroxyurea and 3 patients were not receiving any treatment. The sample size was chosen based on a power calculation using data from a preceding unpublished pilot study in which the mean number of microparticles in control subjects was 3400×10 6 /L and that in ET patients was 7500×10 6 /L. With an alpha of 0.05 this calculation showed that 9 controls and 18 ET patients would provide the analysis with sufficient power. In addition, we investigated 10 healthy controls (6 males and 4 females, median age 46, range 19-59). None of the healthy controls was on antiplatelet medication at the time of blood collection. Controls were significantly younger than ET patients (p=0.015).
Blood collection and isolation of microparticles
Blood samples were drawn early in the morning, before any therapy, with a 21-gauge needle after applying a light tourniquet. After discarding the first 3 mL, blood was collected into a 5 mL tube containing 3.2% citrate (BD, Plymouth, UK). Plasma was prepared within 30 min after blood collection by centrifugation for 20 min at 1550g at room temperature, without brake. Aliquots of plasma were snap-frozen in liquid nitrogen, and then stored at -75°C until use. In order to isolate the microparticles, 250 µL of plasma were thawed on ice for 60 min and then centrifuged for 30 min at 17,570 x g at 20 °C. Subsequently, 225 µL of supernatant (i.e. microparticlefree plasma) were removed. The remaining 25 µL containing the microparticle pellet were resuspended in 225 µL of phosphate-buffered saline (PBS; 154 mM NaCl, 1.4 Table 1 . Characteristics of study objects at enrollment into the study. Data are presented as median (range) or number (%). 
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Phenotypic analysis of plasma-derived microparticles
Flowcytometric analysis was used to quantify and characterize plasma-derived microparticles, as previously described. 20 Briefly, 5 µL of microparticle sample were diluted in 35 µL PBS containing 2.5 mM CaCl2 (pH 7.4). The samples were then incubated for 30 min at room temperature in the dark with 5 µL annexin V-allophycocyanin (Caltag Laboratories, Burlingame, CA, USA) and/or 5 µL fluoresceinisothiocyanate (FITC)-, phycoerythrin (PE)-, peridinin-chlorophyll-protein complex (PerCP)-labeled anti-human monoclonal antibodies, or 5 µL isotype-matched control monoclonal antibodies.
For the phenotypic characterization of microparticles the following cell-specific monoclonal antibodies were used: For TF measurement on microparticles, anti-TF-FITC from American Diagnostics (VD8, IgG1, Stamford, CT, USA) was used in the same experimental conditions. After incubation, 760 µL PBS/calcium buffer were added and the samples were analyzed on a FACS Calibur using Worklist Manager (BD) for 1 min during which the flowcytometer analyzed approximately 55 µL of the suspension. Forward scatter (FSC) and sideward scatter (SSC) were set at logarithmic gain. To distinguish microparticles from events due to noise, microparticles were identified on the basis of their specific FSC and SSC characteristics, with gates set using in vitro platelet activation and microparticle generation data (results not shown), and by annexin V positivity ( Figure 1A and 1B). 21 To identify annexin V-positive events, a threshold was set in a microparticle sample prepared without calcium. The number of microparticles per liter of plasma was calculated as previously described # MPsper minute *(Volume(V) tube/Vminute) *(Vend/ Vstart) * (1000/ Vlabeled)= # events/mL. 7 Data were analyzed with CellQuest-pro software (Becton Dickinson).
Thrombin generation measurements
Thrombin generation in platelet-poor but microparticle-rich plasma, as prepared for microparticle isolation (described above), was measured with the calibrated automated thrombogram method (Thrombinoscope BV, Maastricht, The Netherlands). 22, 23 Thrombin generation was triggered in 80 µL of plasma by different conditions; 1 pM of TF and 4 µM of phospholipids, 4 µM of phospholipids alone, and buffer (no exogenous TF or phospholipids added), using reagents obtained from Thrombinoscope BV. Thrombin generation was measMicroparticles in essential thrombocythemia Thrombinoscope BV) . Three parameters were derived from the thrombin generation curves: lag time (initiation phase of coagulation), endogenous thrombin potential, and peak height. Lag time was defined as the time to reach 1/6 of the peak height. Validation of the calibrated automated thrombogram method showed normalization of non-time-dependent parameters to be mandatory to obtain acceptable inter-assay variations. 23 Intra-assay variations for normalized parameters are typically below 6%, and inter-assay variations below 8%. 23 Therefore, each thrombin generation measurement includes normal pooled plasma and both the endogenous thrombin potential and peak height values are expressed as the ratio of patient's value to the value in normal pooled plasma, expressed in percentages.
Plasma markers of endothelial activation
Plasma concentrations of soluble E-selectin were determined by a commercially available enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions (Diaclone, Cedex, France). Mature vWF and propeptide plasma levels were measured by ELISA as described previously. 24 The half-life of mature vWF is four times that of the propeptide half-life, and due to this difference in half-life their relative concentration is a distinctive indicator of ongoing chronic as opposed to acute endothelial activation. 25 
Statistical analysis
We established the statistical significance of differences in microparticle numbers between groups with the nonparametric Mann-Whitney U and Kruskal-Wallis tests, where appropriate. Bivariate correlations were estimated by Spearman's rank correlation (R). All tests for statistical significance were two-tailed and p values less than 0.05 were considered statistically significant. Analyses were performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Number and phenotypic characterization of microparticles
The total number of microparticles is significantly higher in ET patients (median: 4500×10 6 /L) than in controls (2500×10 6 /L, p=0.039). For most study subjects, more than 90% of circulating microparticles bound to annexin-V, indicating the presence of phosphatidylserine on their membrane ( Figure 1A and 1B) .
The phenotypic characterization of microparticles depicted in Figure 2 showed that the subset composition of the microparticle population (i.e. of platelet -, leukocyte -, endothelial cell or erythrocyte origin) is similar in ET and controls. The large majority of microparticles is of platelet origin in both groups of subjects, as determined by positivity for the platelet markers CD41 and/or CD61 (CD41 ET vs controls: median±SD 95±0.34% vs 95.7±0.7%; p=0, 15) . Accordingly, the number of plateletderived microparticles was greater in ET patients than in controls (CD61 median 4000 vs. 2400×10 6 /L; p=0.043). The levels of the two platelet activation markers CD62P and CD63 were lower on microparticles from ET patients than on those from controls, and this difference was statistically significant for CD63 (median 5.
With regard to endothelium-derived microparticles, the number of microparticles expressing the endothelial marker CD62E was significantly higher in ET patients than in controls (median 875 vs. 
Relation of microparticles with the presence of the JAK2 V617F mutation or pharmaceutical treatment
Neither JAK2 V617F mutation status nor the treatment given (hydroxyurea or aspirin) affected the number or the cellular origin of microparticles, including TF-positive microparticles in ET patients, (data not shown).
CD41-and CD62E-positive microparticles
Since more than 95% of microparticles were positive for CD41 and CD61, we suspected that the CD62E-positive microparticles, constituting 27% of all microparticles in ET patients, but 1% in controls, could also coexpress a platelet marker. We, therefore, analyzed the microparticles with a combination of CD41-FITC/CD62E-PE monoclonal antibodies. Indeed, in both groups 90% of the CD62E positive microparticles also expressed CD41. The CD62E-positive microparticles constituted 24% of the CD41-positive microparticles in ET patients and 1% in controls. When patients with ET were classified according to a risk score, allocating one point for a history of thrombosis, age over 60 years, platelet count over 1000×10 9 /L, and the presence of a cardiovascular risk factor (for example hypertension or diabetes), 26 microparticles with combined expression of CD41/CD62E were increased only in patients with one or more risk factors (Figure 3, p=0.045 ). This correlation was not observed for microparticles originating from other cells.
Plasma markers of endothelial cell activation
Since ET patients had higher levels of CD41/CD62E-positive microparticles, which suggests endothelial activation, we investigated the activation status of endothelium by measuring plasma levels of soluble E-selectin, mature vWF and propeptide. No significant differences in the plasma levels of Eselectin were observed between ET patients (20 ng/mL, range, 5-40) and controls (14 ng/mL; range, 5-41; p=0.52). The removal of microparticles from plasma by centrifugation did not affect the levels of E-selectin (data not shown), indicating that most of the soluble E-selectin was not bound to these microparticles. Furthermore, no correlation was found between soluble E-selectin levels and the number of CD41/CD62E-positive microparticles (data not shown).
ET patients had significantly higher concentrations of mature vWF in plasma than did controls (median 50 vs. 35 nM, p=0.045) but similar concentrations of propeptide (7 vs. 5 nM, p=0.07). The mature vWF and propeptide pattern was, therefore, significantly different in patients and controls, resulting in a higher mature vWF: propeptide ratio, a pattern previously shown to indicate a state of chronic endothelial activation 25 ( Figure 4) . No correlation was found between mature vWF, propeptide and CD41/CD62E-positive microparticles.
Tissue factor-positive microparticles
TF-positive microparticles accounted for less than 1% of all microparticles in both patients and controls. TF was expressed on microparticles also expressing platelet markers and CD62E. The number of microparticles carrying TF was significantly higher (p=0.036) in ET patients (median 1. /L, presence of a cardiovascular risk factor (26): 0=no risk factor, 1=one risk factor, 2= two risk factors, etc. *ET patients have significantly more CD41/CD62E-positive microparticles than controls (p=0.01), and ** ET patients with one or more risk factors have higher numbers of CD41/ CD62E-positive microparticles compared to those ET patients without risk factors (p=0.034).
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boembolic events or positive risk score for thrombosis and TF-positive microparticles.
Thrombin generation
Thrombin generation triggered with 1 pM of TF and 4 µM of phopholipids was increased in microparticle-rich plasma from ET patients as indicated by increased peak height (ET vs. controls: 411 nM [95%CI: 358-465] and 279 nM [95%CI: 196-361], respectively, p=0.01). No differences were found in lag time and endogenous thrombin potential, suggesting attenuated inhibition rather than altered activation or stimulation under these conditions. Since plasma-, possibly microparticle-derived TF may contribute to the initiation of coagulation, the thrombin generation assay was repeated in the absence of additional TF and only 4 µM of phospholipids were added. Again, the peak height was higher for ET patients (325 nM; 95%CI: 289-360) than for controls (171 nM; 95%CI: 94-249; p=0.001). Furthermore, the lag times were on average 4 min shorter for ET patients (12.0 min; 95%CI: 10.7-13.4) than for controls (15.8 min; 95%CI: 12.0-19.7; p=0.04). This latter observation is suggestive of the presence of more TF in plasma and indeed maybe on microparticles from ET patients than from controls. To further characterize the procoagulant potential of plasma and microparticles from patients with ET, the thrombin generation assay was performed in the absence of both TF and phospholipids ( Figure 5 ). Using these conditions, ET patients had a shorter lag time (9.7 min; 95%CI: 8.7-10.7 versus 15.9 min; 95%CI: 10.9-20.9; p=0.001), and an increased peak height (215 nM; 95%CI: 189-241 versus 142 nM; 95%CI: 87-189; p=0.038), indicating endogenous presence of procoagulant phospholipids and TF, possibly provided by microparticles. Indeed, a negative correlation was found between the total number of microparticles and lag time (R= -0.379, p=0.039) and a positive correlation between the total numer of microparticles and peak height (R=0.634, p<0.001) (Figure 6 ). Finally, after removal of microparticles by centrifugation there was no activation of thrombin generation (data not shown), which is compatible with the absence of microparticle-derived TF and phospholipids.
Discussion
This is the first extensive analysis of microparticles and their cellular origin in patients with ET. Like patients with other thromboembolic diseases, ET patients show higher levels of platelet-derived microparticles than healthy subjects. 4, 5, 27 This is not necessarily attributable to higher numbers of platelets because neither in ET patients nor in controls platelet microparticle numbers correlated with platelet numbers. This lack of correlation was also observed in an earlier study, 28 suggesting that microparticle formation may be a regulated rather than a constitutive process. In spite of the large proportion of plateletderived microparticles in ET patients, the actual number of these microparticles with markers of platelet activation (CD62P and CD63) was not increased. This could be because most ET patients were on anti-thrombotic drugs at the time of blood sampling, which may have affected markers of platelet activation; aspirin inhibits the expression of CD62P and CD63 on platelets. 29 Remarkably, half of the ET patients showed a large increase in CD62E-positive microparticles. These CD62E-positive microparticles were not normal endothelial microparticles since they co-expressed CD41, a platelet marker, a finding that we did not observe in other conditions characterized by endothelial perturbation, including diabetes mellitus 20 and renal failure (data not shown). Chirinos et al. 8 described marked elevations of CD62E-positive microparticles in patients with venous thromboembolism, but co-expression with platelet mark- Normal resting endothelial cells do not express Eselectin, but a soluble form of this molecule is released from activated cells. 30 The presence of CD62E-positive microparticles suggest endothelial activation, a finding substantiated by the higher levels of mature vWF in ET. The finding that this was not accompanied by a rise in propeptide levels suggests that the endothelial activation is chronic rather than acute in nature. 25 However, these CD62E-positive microparticles coexpress CD41, a platelet marker. CD62E was not observed on platelets from controls or ET patients (data not shown). An explanation for this double positivity could be an interaction between platelets (or platelet fragments) and endothelial cells resulting in cellular activation and generation of microparticles of bilineage origin. Circulating microparticles with characteristics of two distinct cell populations have been described, and substantiated by confocal immunofluorescence microscopy. 10 Membrane transfer from microparticles to cells resulting in expression of cell lineage-unrelated receptors is also a recognized phenomenon. 31, 32 In these cases microparticles express antibodies of both original cell types, thereby showing that they are the result of direct or indirect cell-cell contact, in this case endothelial cell/platelet activation. It is also conceivable that microparticles acquire CD62E during their formation via expression by the microparticle source, the activated platelet. Passive adherence of CD62E was considered as an alternative explanation. However, we consider this unlikely since there was no relation between microparticle CD62E expression and soluble E-selectin levels and removal of the microparticles from plasma by centrifugation did not affect soluble E-selectin levels, indicating a very low quantity of CD62E on microparticles as compared to soluble E-selectin in the plasma of patients as well as of controls. A low quantity of CD62E on microparticles as compared to soluble E-selectin in the plasma was shown previously for septic patients. 33 Increased numbers of CD41/CD62E-positive microparticles may be of pathophysiological significance since they appear to be related to risk factors for thrombosis in ET. A relation between these microparticles and thrombosis was not apparent in our present study, but the study was not designed to detect such a relation, and had a limited sample size and short follow-up. Higher numbers of CD66acde and CD66b-positive microparticles in ET are likely to be related to granulocyte activation in this condition. 18 The level of TF-positive microparticles was increased in ET patients, but such microparticles accounted for less than 1% of all microparticles in this study, and it is unclear whether this difference is clinically relevant. In this respect, the absence of a correlation between TF-positive microparticles and clinical parameters, such as a history of thromboembolic events or a positive risk score for thrombosis, may be primarily due to a lack of power. TF expression on platelets has been related to the presence of a JAK2 V617F mutation, 34 but a correlation was not observed in our study between TF-positive microparticles and the presence of the JAK2 V617F mutation.
A limitation of this study is that the ages of the control subjects and patients differed significantly. However, we did not find a correlation between older age and microparticles in our study, and such a correlation has not been described in other studies. 35 The thrombin generation measurements showed an increased peak height for assays with 1 pM of TF and 4 µM of phospholipids, which is compatible with a hypercoagulable state in ET patients. 36 The shorter lag times observed for ET patients whose assays were conducted without additional TF and phospholipids provide evidence for the presence of a procoagulant factor, possibly on the membrane of microparticles, in the plasmas of these patients. We suggest that the differences found in thrombin generation are due to microparticles, since removal of phospholipids abolished thrombin generation. This result is compatible with the observation by Pereira et al. 37 that thrombin generation is largely dependent on the number of microparticles in plasma, the only available phospholipid source in such a system. We found a correlation between peak height and the total number of microparticles, as well as for lag time and microparticles under these conditions, suggesting that phospholipids from microparticles and intrinsic or extrinsic (TF) coagulation activators in plasma and/or on the membrane of microparticles indeed account for the observed differences that were abolished after removal of microparticles by centrifugation. In the light of the previously described evidence of the presence of nonmicroparticle bound functional TF in human plasma, 38 future studies should address the question of whether a particular form of plasma TF contributes to the observed differences between microparticle-rich ET plasma and normal plasma.
In conclusion, ET patients have higher numbers of microparticles expressing platelet and endothelial markers, suggesting ongoing endothelial activation. This is confirmed by a signature of chronic endothelial activation given by an elevated level of mature vWF in the presence of a relatively low level of propeptide. Microparticles from ET patients are associated with increased thrombin generation, shortened lag time and increased peak height. CD41/CD62E-positive microparticles are elevated only in ET patients with risk factors for thrombosis. These findings suggest a role for microparticles in thrombosis in ET and this deserves further prospective studies.
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